190 related articles for article (PubMed ID: 30582377)
1. Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight.
Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
J Drug Target; 2019 Sep; 27(8):830-838. PubMed ID: 30582377
[TBL] [Abstract][Full Text] [Related]
2. A novel chalcone-based molecule, BDP inhibits MDA‑MB‑231 triple-negative breast cancer cell growth by suppressing Hsp90 function.
Oh YJ; Seo YH
Oncol Rep; 2017 Oct; 38(4):2343-2350. PubMed ID: 28849241
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
4. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells.
Kim SY; Lee IS; Moon A
Chem Biol Interact; 2013 May; 203(3):565-72. PubMed ID: 23562496
[TBL] [Abstract][Full Text] [Related]
5. Advances in chalcones with anticancer activities.
Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
[TBL] [Abstract][Full Text] [Related]
6. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer.
WalyEldeen AA; Sabet S; El-Shorbagy HM; Abdelhamid IA; Ibrahim SA
Chem Biol Interact; 2023 Jan; 369():110297. PubMed ID: 36496109
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
8. Chalcones against the hallmarks of cancer: a mini-review.
de Souza PS; Bibá GCC; Melo EDDN; Muzitano MF
Nat Prod Res; 2022 Sep; 36(18):4809-4826. PubMed ID: 34865580
[TBL] [Abstract][Full Text] [Related]
9. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
10. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
11. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer.
Huang SP; Liu PY; Kuo CJ; Chen CL; Lee WJ; Tsai YH; Lin YF
J Hematol Oncol; 2017 Jun; 10(1):114. PubMed ID: 28576130
[TBL] [Abstract][Full Text] [Related]
12. Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?
Boumendjel A; Ronot X; Boutonnat J
Curr Drug Targets; 2009 Apr; 10(4):363-71. PubMed ID: 19355861
[TBL] [Abstract][Full Text] [Related]
13. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
Roberts LS; Yan P; Bateman LA; Nomura DK
ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
[TBL] [Abstract][Full Text] [Related]
14. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
15. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
[TBL] [Abstract][Full Text] [Related]
16. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
Xiao J; Gao M; Diao Q; Gao F
Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
[TBL] [Abstract][Full Text] [Related]
17. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
18. New strategies for triple-negative breast cancer--deciphering the heterogeneity.
Mayer IA; Abramson VG; Lehmann BD; Pietenpol JA
Clin Cancer Res; 2014 Feb; 20(4):782-90. PubMed ID: 24536073
[TBL] [Abstract][Full Text] [Related]
19. Autophagy: A promising target for triple negative breast cancers.
Abd El-Aziz YS; Gillson J; Jansson PJ; Sahni S
Pharmacol Res; 2022 Jan; 175():106006. PubMed ID: 34843961
[TBL] [Abstract][Full Text] [Related]
20. Natural and Synthetic Chalcones: Potential Impact on Breast Cancer.
Dadi V; Malla RR; Siragam S
Crit Rev Oncog; 2023; 28(4):27-40. PubMed ID: 38050979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
